Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2138 plus chemotherapy with pembrolizumab versus placebo plus chemotherapy with or without pembrolizumab in first-line HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
2025-524557-14-00Phase 3Authorised
- Sponsor
- Astellas Pharma
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing ASP2138 plus chemotherapy with pembrolizumab with Placebo plus chemotherapy with or without pembrolizumab (2 arms). Primary endpoints: Overall survival and Progression-free survival by blinded independent central review. Planned start Oct 2026; status: authorised.
02
Drugs
ASP2138
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-524557-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524557-14-00.